Related Experiment Video

Updated: Jul 4, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K

Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile

Ana C Veneziani1, Suku Sneha1, Amit M Oza1,2

  • 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 2, 2024
PubMed

Insights

Researchers are developing precision medicines targeting cancer cell surface proteins. A new study shows a B7-H4 antibody-drug conjugate is effective against resistant ovarian cancer cells in preclinical models.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Precision medicine aims to target tumor-specific antigens for enhanced efficacy and reduced toxicity.
  • B7-H4 is a tumor-associated antigen frequently overexpressed on various cancer cells, including those in ovarian cancer.
  • Resistance to conventional therapies remains a significant challenge in ovarian cancer treatment.

Purpose of the Study:

  • To evaluate the therapeutic potential of targeting the B7-H4 antigen in ovarian cancer.
  • To assess the preclinical efficacy of a B7-H4-directed antibody-drug conjugate (ADC).

Main Methods:

  • Demonstration of high B7-H4 antigen expression on resistant ovarian cancer cells.
  • Preclinical evaluation of a novel B7-H4-targeted ADC.

Main Results:

  • High expression of B7-H4 was confirmed on ovarian cancer cells, particularly those resistant to therapy.
  • The B7-H4-directed ADC exhibited promising preclinical anti-tumor activity.

Conclusions:

  • B7-H4 represents a viable therapeutic target for ovarian cancer, especially in resistant cases.
  • B7-H4-directed ADCs hold potential as a novel treatment strategy for ovarian cancer.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.8K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.0K

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
72.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K